The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
(10 - 33) Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21.2 - Manufacture of pharmaceutical preparations
188 - 192 jobs Number of planned job losses
Announcement Date
9 November 2018
Employment effect (start)
Foreseen end date
Description
The pharmaceutical company Corden Pharma announced its intention to start a restructuring plan for the plant in Sermoneta (province of Latina) which entails the dismissal of 192 out of 491 workers currently employed at the site.
The decision has been justified by the management as a necessary step to recover from the difficult economic and financial situation the company is facing. Due to the same reason, the company has stopped the payment of wages for October and of the supplementary monthly payment foreseen by the sectoral collective agreement.
Negotiations between the company, trade unions, and local institutions have started with the goal of reducing the number of dismissals and their social consequences through the use of shock absorber instruments.
Update, 21/01/2019: Thanks to an agreement signed between the company, the trade unions and workplace employee representatives, dismissals for 188 workers of Corden Pharma were withdrawn. The agreement entails the use of social shock absorber instruments (Cassa Integrazione Straordinaria) for 400 employees of the plant, and the suspension of the payment of the productivity bonus and the 14th supplementary monthly payment foreseen by the chemical industry's sectoral collective agreement until 2024 (after which it will be reinstated automatically). The mobility procedure will remain open to all those workers who wish to leave voluntarily, whose exit will be economically incentivesed.
Sources
Citation
Eurofound (2018), Corden Pharma, Internal restructuring in Italy, factsheet number 95941, European Restructuring Monitor. Dublin, https://dev.eurofound.europa.eu/restructuring-events/detail/95941.
This working paper offers a comprehensive methodological overview of the European Restructuring Monitor (ERM) databases. Even though the methodology has not changed over time, new categories have been added, and the way it has been used by researchers and policymakers...
This Eurofound research paper explores key trends in restructuring in recent years, highlighting the companies that announced the largest job losses and job gains in the EU. It builds on an analysis of company announcements recorded in Eurofound’s European Restructuring...
In 2023, thousands of workers in big tech lost their jobs. Meta, Amazon, Google, Apple, Microsoft and Salesforce had been considered to offer good and secure jobs up to this point. Giants of the information and communication technology (ICT) sector,...
In 2024, the automotive sector in the EU came to the fore in public and policy discussions. The focus was on the slowdown in electric vehicle (EV) sales, rising global competition, belated investments in new technologies, and the potential closure...
The more employee monitoring resembles surveillance – with its systematic, continuous and detailed tracking of employees' activities, behaviours or communications – the greater the potential for infringement of both privacy and data protection rights. Although the EU General Data Protection...
Since 2013, Eurofound's ERM database on restructuring-related legislation has been documenting regulatory developments in the Member States of the European Union and Norway which are explicitly or implicitly linked to anticipating and managing change. The most recent update to the...